EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)

Their core work

EF-CLIF is a Barcelona-based research foundation dedicated to understanding and treating chronic liver failure, particularly acute-on-chronic liver failure (ACLF) and decompensated cirrhosis. They drive clinical research into new therapies — from liver dialysis devices and drug combinations (simvastatin, rifaximin) to microbiome-based diagnostics and biomarker discovery. Their work spans the full translational pipeline: identifying disease mechanisms through multi-omics analysis, developing diagnostic tools like nanobiosensors, and running clinical evaluations of experimental treatments. They also contribute to international coordination on microbiome research standards and personalized medicine frameworks.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), EF-CLIF focused on evaluating specific therapeutic interventions — nanoporous carbon materials, liver dialysis devices, and drug repurposing (simvastatin, rifaximin) — primarily as a consortium participant contributing clinical expertise. From 2019 onward, they shifted decisively toward systems-level understanding: microbiome signatures, multi-omics biomarkers, and combinatorial therapy design, now leading projects as coordinator. This evolution reflects a move from testing individual treatments to building predictive, data-driven frameworks for personalized cirrhosis management.

EF-CLIF is moving toward precision medicine for liver disease — combining microbiome data, multi-omics, and computational approaches to predict and personalize treatment, making them a strong partner for data-intensive clinical research.

How they like to work

EF-CLIF operates as both a consortium leader and an active partner, with a near-even split (3 coordinated, 4 as participant). Their coordinator role emerged in later, larger projects (MICROB-PREDICT at EUR 2.3M), suggesting growing institutional confidence and reputation. With 79 unique partners across 15 countries, they maintain a broad European network — characteristic of an organization that serves as a disease-area hub, attracting diverse clinical, diagnostic, and computational partners around liver failure research.

EF-CLIF has collaborated with 79 distinct partners across 15 countries, forming a wide European network centered on hepatology research. Their participation in the IHMCSA coordination action also connects them to the global microbiome research community.

What sets them apart

EF-CLIF occupies a rare niche as a foundation entirely dedicated to chronic liver failure research — not a university department or hospital unit, but a focused research entity built around one disease area. This gives them deep domain authority and continuity that generalist institutions cannot match. Their combination of clinical trial coordination, microbiome-based diagnostics, and therapy development makes them a one-stop partner for anyone entering the liver disease space in Europe.

Highlights from their portfolio

• MICROB-PREDICT
  Their flagship project (EUR 2.3M, coordinated) — uses microbiome biomarkers and multi-omics to predict cirrhosis decompensation, representing their strategic pivot toward precision hepatology.
• DECISION
  Second-largest coordinated project (EUR 1.3M) applying systems biology to identify new combinatorial therapies for decompensated cirrhosis — bridges their clinical and computational expertise.
• IHMCSA
  International microbiome coordination action that extends EF-CLIF's reach beyond liver disease into global standards-setting for human microbiome research and health data science.